Trial · NCT03989349
Adverse event totals18
The totals the trial posted for each group.
1 to 18 of 18
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 0 | 519 |
| Total, all-cause mortality | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 0 | 263 |
| Total, all-cause mortality | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q4W | 0 | 79 |
| Total, all-cause mortality | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q8W | 0 | 77 |
| Total, all-cause mortality | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 0 | 77 |
| Total, all-cause mortality | Maintenance Period (Week 16- Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 0 | 84 |
| Total, other adverse events | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 71 | 519 |
| Total, other adverse events | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 40 | 263 |
| Total, other adverse events | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q4W | 17 | 79 |
| Total, other adverse events | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q8W | 11 | 77 |
| Total, other adverse events | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 26 | 77 |
| Total, other adverse events | Maintenance Period (Week 16- Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 16 | 84 |
| Total, serious adverse events | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 13 | 519 |
| Total, serious adverse events | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 3 | 263 |
| Total, serious adverse events | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q4W | 6 | 79 |
| Total, serious adverse events | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Q8W | 0 | 77 |
| Total, serious adverse events | Maintenance Period (Week 16- Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W | 2 | 77 |
| Total, serious adverse events | Maintenance Period (Week 16- Week 48): Placebo Q4W Re-assigned to Placebo Q4W | 1 | 84 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03989349/event-totals